Navigation Links
Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
Date:10/29/2009

ies to people afflicted with these diseases. We remain fully committed to the success of Amicus," concluded John F. Crowley.

Financial Guidance:

Based on current projections of net operating expense, the Company reiterates its expectation to end 2009 with approximately $70-$80 million in cash, cash equivalents and marketable securities. Additionally, the Company expects that its current cash, cash equivalents and marketable securities together with the fourth quarter $5.2 million payment from Shire will be sufficient to fund operations and capital expenditure requirements into the second half of 2011.

Third Quarter 2009 Results Summary

On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.59 per share ($0.51 per share on a non-GAAP basis) for the three months ended September 30, 2009. As of September 30, 2009, cash, cash equivalents and marketable securities totaled $89.3 million.

Clinical Program Updates

Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease

In the second quarter of 2009, Amicus announced that the Company reached agreement with the FDA on the key protocol design elements of its pivotal trial, including the use of the surrogate primary endpoint of the change in the amount of kidney interstitial capillary GL-3, the substrate that accumulates in the cells of Fabry patients. In addition, the FDA is in agreement that the Company is eligible to seek Accelerated Approval for Amigal according to Subpart H regulations. Amicus began submitting the Phase 3 protocol to investigational sites worldwide in June 2009 and patient enrollment and dosing are now underway.

Furthermore, Amicus previously reported that it completed a series of discussions with the EMEA regarding the clinical study requ
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: ... areas, announced the closing of an underwritten public offering of ... to an aggregate 3,500,000 shares of common stock, at an ... The warrants have a per share exercise price of $5.00, ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by Instrument (Liquid ... Valves, Guages, Seals), Accessories, Services, End User (Biotechnology, ... provides a detailed overview of the major drivers, ... impacting the preparative and process chromatography market along ...
(Date:12/24/2014)... SoundConnect’s 2015 next generation ... communication technology, provide continued education and inform users ... demonstrates online communication features and benefits; empowering users ... innovative and powerful tools. , According to SoundConnect’s ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application and ... manufacturing process, and product cost structure. Production is ... also covers upstream raw materials, equipment, downstream client ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... Pulmo BioTech Inc. (OTC Bulletin Board: PLMO; Frankfort ... receive at least $3.3 million pursuant to the ... letter of intent with Biotechnology Consulting Poland Sp. ... Product Candidate PulmoBind(TM) development work, clinical trials and ...
... produced liver cells from adult skin cells using the induced ... the University of Edinburgh,s MRC Centre for Regenerative Medicine, paves ... that can be used for in vitro hepatic disease models. ... cell type used in predictive drug toxicology. These cells are ...
... The scientists and engineers who introduced the world ... the next level of friendly competition designed to ... operations of useful robots whose dimensions are measured ... National Institute of Standards and Technology (NIST), in ...
Cached Biology Technology:Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market 2Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market 3Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market 4Scientists develop novel method to generate functional hepatocytes for drug testing 2Is your microrobot up for the (NIST) challenge? 2
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... including technology and tech stocks, releases video from the CES ... and security consultant Apollo Robbins . Apollo ... the Wocket™ biometric smart wallet, a product of NXT-ID, Inc. ...
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight ... watermarking and fingerprinting markets. Watermarking aims to control ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 2
... National Human Genome Center at Shanghai (South Center, hereafter) ... District in Shanghai. To commemorate this important event, ,which ... we specially organize a series of mini-reviews for ,this ... the attention of the Chinese life science research workers ...
... world,s premier science and technology news magazines, released its list ... projects involving physicists from Louisiana Tech University in its Top ... over 5,000 scientists and engineers from 26 nations, ranked #2 ... Markus Wobisch led a team from Louisiana Tech that is ...
... MEETING HIGHLIGHTS BREAKTHROUGH RESEARCH IN UNDERSTANDING GENETIC AND ... Although racial and ethnic differences in ... known, little is understood about the underlying causes ... seemingly intractable problem. The American Association for Cancer ...
Cached Biology News:Human genomics in China 2Human genomics in China 3Human genomics in China 4Human genomics in China 5Human genomics in China 6Human genomics in China 7Human genomics in China 8Human genomics in China 9Human genomics in China 10Human genomics in China 11Louisiana Tech physicists highlight top 10 science stories of 2008 2American Association for Cancer Research hosts Science of Health Care Disparities Meeting 2
Imject Freund's Incomplete Adjuvant (FIA)...
... XL extends the MSn performance of the ... tools to generate extensive structural information for ... , Multiple dissociation techniques (PQD, ETD, ... unpredicted metabolites , Fast polarity switching for ...
... effective - Utilizes hands-off homogenization through a vortex ... grinding - Extract DNA without hand grinding; eliminating ... , Robust tubes - Includes tough ... tube breakage , Flexible format - ...
... The LXQ linear ion trap mass ... paced analytical laboratory., The LXQ linear ion ... discovery and proteomic applications, delivering the fast ... Thermo linear ion trap at an attractive ...
Biology Products: